Proteolysis targeting chimeras (PROTACs), known for their ability to interact with previously undruggable targets, are rising in popularity as cancer therapeutics. However, performing biophysical assays to quantify the strength of a degrader's molecular interactions with binding partners is challenging due to factors including small sample amounts, lack of mass changes upon target binding, and complex protocols. Researchers can simplify and quickly perform these binding assays using Spectral Shift technology on NanoTemper's Dianthus platform.
Download this webinar from NanoTemper to learn how scientists quickly characterized PROTAC binary and ternary interactions using Spectral Shift technology.
